2Seventy Bio IncNASDAQ:TSVT
- LAST PRICE4.7500
- TODAY'S CHANGE (%)-0.0600 (-1.2474%)
- Bid / Lots4.7600/ 1
- Ask / Lots4.9300/ 1
- Open / Previous Close4.8000 / 4.8100
- Day Range
- 52 Week Range
- Volume199,732
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TSVT |
|---|---|---|
| 09:32 ET | 3150 | 4.765 |
| 09:36 ET | 551 | 4.8 |
| 09:39 ET | 100 | 4.785 |
| 09:45 ET | 1110 | 4.79 |
| 09:50 ET | 1400 | 4.76 |
| 09:54 ET | 2900 | 4.8 |
| 09:56 ET | 2200 | 4.8 |
| 09:59 ET | 100 | 4.805 |
| 10:01 ET | 200 | 4.805 |
| 10:03 ET | 900 | 4.8 |
| 10:10 ET | 100 | 4.795 |
| 10:15 ET | 9900 | 4.8 |
| 10:19 ET | 600 | 4.785 |
| 10:21 ET | 545 | 4.785 |
| 10:24 ET | 1500 | 4.79 |
| 10:33 ET | 304 | 4.754 |
| 10:44 ET | 400 | 4.71 |
| 10:48 ET | 100 | 4.71 |
| 10:50 ET | 1127 | 4.73 |
| 10:53 ET | 101 | 4.73 |
| 10:55 ET | 200 | 4.72 |
| 11:04 ET | 100 | 4.72 |
| 11:08 ET | 517 | 4.74 |
| 11:09 ET | 652 | 4.73 |
| 11:11 ET | 200 | 4.71 |
| 11:13 ET | 167 | 4.69 |
| 11:15 ET | 300 | 4.68 |
| 11:18 ET | 200 | 4.68 |
| 11:20 ET | 600 | 4.68 |
| 11:22 ET | 584 | 4.67 |
| 11:24 ET | 505 | 4.68 |
| 11:26 ET | 401 | 4.68 |
| 11:27 ET | 200 | 4.67 |
| 11:29 ET | 100 | 4.67 |
| 11:31 ET | 300 | 4.66 |
| 11:33 ET | 462 | 4.67 |
| 11:36 ET | 350 | 4.65 |
| 11:38 ET | 605 | 4.67 |
| 11:44 ET | 766 | 4.6811 |
| 11:45 ET | 2913 | 4.6899 |
| 11:47 ET | 126 | 4.7 |
| 11:49 ET | 100 | 4.7 |
| 11:51 ET | 1105 | 4.71 |
| 11:54 ET | 100 | 4.725 |
| 11:58 ET | 500 | 4.71 |
| 12:03 ET | 2800 | 4.725 |
| 12:05 ET | 100 | 4.725 |
| 12:14 ET | 250 | 4.74 |
| 12:16 ET | 532 | 4.75 |
| 12:18 ET | 100 | 4.76 |
| 12:20 ET | 142 | 4.77 |
| 12:23 ET | 100 | 4.76 |
| 12:25 ET | 276 | 4.77 |
| 12:27 ET | 175 | 4.77 |
| 12:30 ET | 500 | 4.76 |
| 12:32 ET | 744 | 4.77 |
| 12:34 ET | 100 | 4.745 |
| 12:38 ET | 900 | 4.72 |
| 12:39 ET | 715 | 4.72 |
| 12:41 ET | 238 | 4.73 |
| 12:43 ET | 100 | 4.73 |
| 12:48 ET | 1600 | 4.71 |
| 12:50 ET | 2900 | 4.72 |
| 12:52 ET | 100 | 4.7 |
| 12:54 ET | 2072 | 4.695 |
| 12:57 ET | 100 | 4.69 |
| 12:59 ET | 600 | 4.69 |
| 01:03 ET | 100 | 4.68 |
| 01:06 ET | 494 | 4.68 |
| 01:08 ET | 100 | 4.66 |
| 01:10 ET | 100 | 4.66 |
| 01:12 ET | 100 | 4.66 |
| 01:14 ET | 100 | 4.66 |
| 01:17 ET | 100 | 4.66 |
| 01:24 ET | 232 | 4.68 |
| 01:26 ET | 1154 | 4.68 |
| 01:28 ET | 100 | 4.68 |
| 01:30 ET | 241 | 4.6715 |
| 01:33 ET | 412 | 4.65 |
| 01:35 ET | 714 | 4.66 |
| 01:39 ET | 500 | 4.635 |
| 01:44 ET | 100 | 4.62 |
| 01:46 ET | 313 | 4.615 |
| 01:48 ET | 987 | 4.62 |
| 01:50 ET | 600 | 4.62 |
| 01:51 ET | 753 | 4.62 |
| 01:53 ET | 301 | 4.62 |
| 01:55 ET | 100 | 4.62 |
| 01:57 ET | 244 | 4.63 |
| 02:00 ET | 600 | 4.64 |
| 02:02 ET | 500 | 4.65 |
| 02:11 ET | 100 | 4.65 |
| 02:15 ET | 100 | 4.64 |
| 02:18 ET | 100 | 4.64 |
| 02:22 ET | 1303 | 4.65 |
| 02:24 ET | 300 | 4.64 |
| 02:26 ET | 207 | 4.65 |
| 02:33 ET | 566 | 4.62 |
| 02:36 ET | 200 | 4.61 |
| 02:38 ET | 365 | 4.61 |
| 02:40 ET | 700 | 4.62 |
| 02:42 ET | 200 | 4.62 |
| 02:44 ET | 100 | 4.62 |
| 02:45 ET | 100 | 4.62 |
| 02:47 ET | 100 | 4.62 |
| 02:49 ET | 200 | 4.62 |
| 02:51 ET | 300 | 4.62 |
| 02:54 ET | 600 | 4.615 |
| 02:58 ET | 300 | 4.615 |
| 03:00 ET | 3120 | 4.62 |
| 03:02 ET | 1517 | 4.63 |
| 03:03 ET | 100 | 4.62 |
| 03:07 ET | 500 | 4.64 |
| 03:09 ET | 200 | 4.645 |
| 03:12 ET | 900 | 4.64 |
| 03:14 ET | 300 | 4.63 |
| 03:16 ET | 100 | 4.63 |
| 03:18 ET | 100 | 4.63 |
| 03:20 ET | 200 | 4.64 |
| 03:21 ET | 100 | 4.63 |
| 03:23 ET | 1076 | 4.65 |
| 03:25 ET | 100 | 4.64 |
| 03:27 ET | 1038 | 4.62 |
| 03:30 ET | 100 | 4.61 |
| 03:32 ET | 300 | 4.62 |
| 03:34 ET | 300 | 4.62 |
| 03:36 ET | 1661 | 4.635 |
| 03:38 ET | 1118 | 4.65 |
| 03:39 ET | 200 | 4.65 |
| 03:41 ET | 200 | 4.64 |
| 03:43 ET | 549 | 4.635 |
| 03:45 ET | 1900 | 4.645 |
| 03:48 ET | 500 | 4.645 |
| 03:50 ET | 200 | 4.645 |
| 03:52 ET | 1700 | 4.645 |
| 03:54 ET | 2119 | 4.645 |
| 03:56 ET | 1259 | 4.66 |
| 03:57 ET | 500 | 4.66 |
| 03:59 ET | 60822 | 4.75 |
Yesterday
Oct 2, 2024
2seventy bio, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by 2seventy bio, Inc. (TSVT), from 10:20AM ET on Wednesday Oct 02, 2024 by Dow Jones
10:20AM ET on Wednesday Oct 02, 2024 by Dow JonesBronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against 2seventy bio, Inc. (TSVT) And Encourages Shareholders to Reach Out, from 10:01AM ET on Wednesday Oct 02, 2024 by Dow Jones
10:01AM ET on Wednesday Oct 02, 2024 by Dow Jones
Oct 1, 2024
2seventy bio, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by 2seventy bio, Inc. (TSVT), from 3:46PM ET on Tuesday Oct 01, 2024 by Dow Jones
3:46PM ET on Tuesday Oct 01, 2024 by Dow JonesSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT, from 3:16PM ET on Tuesday Oct 01, 2024 by Dow Jones
3:16PM ET on Tuesday Oct 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
2Seventy Bio Inc | 244.6M | -1.6x | --- |
Nektar Therapeutics | 239.3M | -1.4x | --- |
Chromadex Corp | 263.5M | -192.8x | --- |
Enanta Pharmaceuticals Inc | 237.1M | -2.0x | --- |
CytomX Therapeutics Inc | 88.3M | 8.2x | --- |
Editas Medicine Inc | 263.9M | -1.4x | --- |
Company Information
2seventy bio, Inc. is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The Company is focused on the commercialization and development of Abecma (idecabtagene vicleucel). Abecma is its B cell maturation antigen (BCMA)-targeted CAR T cell therapy for multiple myeloma, in collaboration with their partner Bristol Myers Squibb (BMS). ABECMA is a BCMA-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma uses a lentiviral vector (LVV), to deliver a chimeric antigen receptor (CAR), with the potential to program a patient’s own T cells to recognize the plasma cell specific BCMA, protein on the cell surface.
Contact Information
- Headquarters
- 60 Binney StreetCAMBRIDGE, MA, United States 02210
- Phone
- 339-499-9300
- Fax
- 302-636-5454
Executives
- Chairman of the Board
- Nick Leschly
- President, Chief Executive Officer, Director
- William Baird
- Chief Financial Officer
- Victoria Eatwell
- Senior Vice President - Quality & Head of Operations
- Jessica Snow
- Lead Independent Director
- Denice Torres
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $244.6M |
|---|---|
Revenue (TTM) | $44.1M |
Shares Outstanding | 51.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.06 |
Book Value | $5.04 |
P/E Ratio | -1.6x |
Price/Sales (TTM) | 5.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -489.86% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
